Perimembrane Aurora-A Expression is a Significant Prognostic Factor in Correlation with Proliferative Activity in Non-Small-Cell Lung Cancer (NSCLC)-Reference-Cited by-同舟云学术

Perimembrane Aurora-A Expression is a Significant Prognostic Factor in Correlation with Proliferative Activity in Non-Small-Cell Lung Cancer (NSCLC)

Published:2007-11-28 Issue:2 Volume:15 Page:547-554
ISSN:1068-9265
Container-title:Annals of Surgical Oncology
language:en
Short-container-title:Ann Surg Oncol

Author:

Ogawa Eiji,Takenaka Kazumasa,Katakura Hiromichi,Adachi Masashi,Otake Yosuke,Toda Yoshinobu,Kotani Hirokazu,Manabe Toshiaki,Wada Hiromi,Tanaka Fumihiro

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Surgery

Link

http://link.springer.com/content/pdf/10.1245/s10434-007-9653-8.pdf

Reference36 articles.

1. Mountain CF. Revisions in the international system for lung cancer. Chest 1997; 111:1710–7

2. Naruke T, Goya T, Tsuchiya R, Suemasu K. Prognosis and survival in resected lung carcinoma based on the new international staging system. J Thorac Cardiovasc Surg 1998; 96:440–7

3. Tanaka F, Yanagihara K, Otake Y, et al. Surgery for non-small cell lung cancer: postoperative survival based on the revised tumor-node-metastasis classification and its time trend. Eur J Cardiothorac Surg 2000; 18:147–55

4. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129–39

5. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304:1497–500

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Knowledge mapping of AURKA in Oncology：An advanced Bibliometric analysis (1998–2023);Heliyon;2024-06

2. Differential expression and analysis of extrachromosomal circular DNAs as serum biomarkers in lung adenocarcinoma;Journal of Clinical Laboratory Analysis;2022-04-20

3. A first-in-human phase 1 and pharmacological study of TAS-119, a novel selective Aurora A kinase inhibitor in patients with advanced solid tumours;British Journal of Cancer;2020-10-06

4. Expression of FOXM1 and Aurora-A predicts prognosis and sorafenib efficacy in patients with hepatocellular carcinoma;Cancer Biomarkers;2020-07-03

5. Inhibition of Aurora A enhances radiosensitivity in selected lung cancer cell lines;Respiratory Research;2019-10-23